Results 91 to 100 of about 37,717 (247)
From Interferon Signature to the Clinical Landscape: Type I Interferonopathies
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz +13 more
wiley +1 more source
ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell +11 more
wiley +1 more source
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt +7 more
wiley +1 more source
Key Clinical Message Rare but severe, immune‐related adverse events such as myositis and sclerosing cholangitis can occur with immune checkpoint inhibitors in lung cancer treatment.
Takafumi Yamano +3 more
doaj +1 more source
Two Cases of Orbital Myositis as a Rare Feature of Lyme Borreliosis
Myositis has been reported as a rare manifestation of Lyme disease, and the Lyme disease spirochetes can be an important consideration in the differential diagnosis of unusual cases of myositis,
Arnaud Sauer +2 more
doaj +1 more source
ABSTRACT Thymoma is the most common tumor of the anterior mediastinum. Approximately 20%–30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG.
Benjamin Claytor +5 more
wiley +1 more source
Perianesthetic Complications in Genetic Mitochondrial Disease: A Review of Case Reports
ABSTRACT Background Genetic mitochondrial diseases (GMDs) are a large group of genetically and clinically heterogeneous disorders caused by defects in genes encoding mitochondrial components. GMDs are grouped into named syndromes based on clinical presentation, for example, Leigh syndrome (LS).
Brittany M. Johnson, Simon C. Johnson
wiley +1 more source
This large‐scale retrospective study of 5778 primary Sjögren's disease (SjD) patients, stratified by diagnostic age, defines a distinct clinical and immunological profile for early‐diagnosed (<45 years) disease. We identified early diagnosis as an independent risk factor for hypergammaglobulinemia and interstitial lung disease, underpinned by a ...
Yuan Ning +7 more
wiley +1 more source
Sera from patients with anti‐MDA5‐positive dermatomyositis‐associated interstitial lung disease (ILD) exhibit significantly higher type I interferon (IFN‐I) bioactivity and interferon‐stimulated gene‐inducing activity compared to anti‐ARS‐positive ILD and healthy controls.
Shohei Nakamura +3 more
wiley +1 more source
Role of defensins in immunothrombosis
Defensins are important proteins that link the immune system and blood clotting, playing a key role in immunothrombosis. α‐defensins mainly come from neutrophils, while β‐defensins are produced by epithelial cells and platelets. These proteins help form blood clots in several ways: they slow down clot breakdown (fibrinolysis), activate platelets, and ...
Yuebing Wang +7 more
wiley +1 more source

